阿尔茨海默病治疗再传好消息！礼来公司新药终获美国FDA批准_老虎社区_美港股上老虎

阿尔茨海默病治疗再传好消息！礼来公司新药终获美国FDA批准

环球市场播报04:52

礼来公司的阿尔茨海默病治疗药物在美国获得批准，成为第二种减缓这种折磨600万美国人的夺脑疾病进展的药物。对于礼来及其投资者来说，这是一个巨大的胜利，自从三年前该药物在临床试验中显示出前景以来，他们一直热切期待着它。这种名为Kisunla的药物在获得批准的过程中经历了多次监管延误。它将与卫材公司的Leqembi竞争，Leqembi已于2023年初在美国上市。礼来公司股价周二在纽约收盘下跌0.8%。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2448690194?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/5f409b88b7d185dd87d8d5e79ef0cebb","is_english":false,"pubTime":"2024-07-03 04:52","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2448690194","market":"us","top_or_hot":-1,"title":"阿尔茨海默病治疗再传好消息！礼来公司新药终获美国FDA批准","media":"环球市场播报","content":"<div>\n<p>礼来公司的阿尔茨海默病治疗药物在美国获得批准，成为第二种减缓这种折磨600万美国人的夺脑疾病进展的药物。对于礼来及其投资者来说，这是一个巨大的胜利，自从三年前该药物在临床试验中显示出前景以来，他们一直热切期待着它。这种名为Kisunla的药物在获得批准的过程中经历了多次监管延误。它将与卫材公司的Leqembi竞争，Leqembi已于2023年初在美国上市。礼来公司股价周二在纽约收盘下跌0.8%。...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2024-07-03/doc-incauxat7130352.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿尔茨海默病治疗再传好消息！礼来公司新药终获美国FDA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿尔茨海默病治疗再传好消息！礼来公司新药终获美国FDA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-03 04:52 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2024-07-03/doc-incauxat7130352.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>礼来公司的阿尔茨海默病治疗药物在美国获得批准，成为第二种减缓这种折磨600万美国人的夺脑疾病进展的药物。对于礼来及其投资者来说，这是一个巨大的胜利，自从三年前该药物在临床试验中显示出前景以来，他们一直热切期待着它。这种名为Kisunla的药物在获得批准的过程中经历了多次监管延误。它将与卫材公司的Leqembi竞争，Leqembi已于2023年初在美国上市。礼来公司股价周二在纽约收盘下跌0.8%。...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2024-07-03/doc-incauxat7130352.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2265009873.SGD","symbol_name":"Eastspring Investments - Global Growth Equity AS SGD-H","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-07-03/doc-incauxat7130352.shtml","article_id":"2448690194","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/5f409b88b7d185dd87d8d5e79ef0cebb"],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-07-03/doc-incauxat7130352.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2448690194","pubTimestamp":1719953520,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"礼来公司的阿尔茨海默病治疗药物在美国获得批准，成为第二种减缓这种折磨600万美国人的夺脑疾病进展的药物。这种名为Kisunla的药物在获得批准的过程中经历了多次监管延误。它将与卫材公司的Leqembi竞争，Leqembi已于2023年初在美国上市。　　礼来公司股价周二在纽约收盘下跌0.8%。　　礼来公司表示，这种治疗阿尔茨海默病的药物在治疗的第一年将花费3.2万美元。这比一个中等身材的人在Leqembi每年26500美元的价格略高。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","BK4588":"碎股","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4581":"高盛持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LLY":"礼来","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4585":"ETF&股票定投概念","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK4007":"制药","LU0238689110.USD":"贝莱德环球动力股票基金","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0385154629.USD":"贝莱德营养科学基金A2","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H"},"translate_title":"Alzheimer's disease treatment spreads good news again! Eli Lilly's new drug finally approved by the US FDA","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/edde271743b4cf41223951edfeb58b02","symbols_score_info":{"LLY":1},"content_text":"礼来公司的阿尔茨海默病治疗药物在美国获得批准，成为第二种减缓这种折磨600万美国人的夺脑疾病进展的药物。对于礼来及其投资者来说，这是一个巨大的胜利，自从三年前该药物在临床试验中显示出前景以来，他们一直热切期待着它。这种名为Kisunla的药物在获得批准的过程中经历了多次监管延误。它将与卫材公司的Leqembi竞争，Leqembi已于2023年初在美国上市。礼来公司股价周二在纽约收盘下跌0.8%。今年到目前为止，由于减肥和糖尿病产品销售的快速增长，该公司股价已经飙升了50%以上。卫材的合作伙伴百健股价下跌1.3%礼来公司表示，这种治疗阿尔茨海默病的药物在治疗的第一年将花费3.2万美元。这比一个中等身材的人在Leqembi每年26500美元的价格略高。但是，如果大脑斑块（药物去除的有毒物质）下降到最低水平，医生可以停止治疗，大约一年后，他们在许多人的试验中都做到了这一点。","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}